Phase III dose-comparison study of glatiramer acetate for multiple sclerosis.

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F11%3A33116068" target="_blank" >RIV/61989592:15110/11:33116068 - isvavai.cz</a>

Alternative codes found

RIV/00843989:_____/11:00103087

Result on the web

—

DOI - Digital Object Identifier

—

Result language

angličtina

Original language name

Phase III dose-comparison study of glatiramer acetate for multiple sclerosis.

Original language description

To evaluate the safety, tolerability, and efficacy of glatiramer acetate (GA) 40 mg compared to a 20mg dose. METHODS: Patients with multiple sclerosis (MS) with ? 1 documented relapse in 12 months prior to screening, or ? 2 documented relapses in 24 months prior to screening, and Expanded Disability Status Scale (EDSS) score 0 to 5.5 were enrolled. Patients were evaluated at screening, baseline, and at months 1, 2, 3, 6, 9, and 12. Primary endpoint was rate of confirmed relapses observed during 12-monthstudy. Analysis was by intent-to-treat.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FH - Neurology, neuro-surgery, nuero-sciences

OECD FORD branch

—

Project

—

Continuities

S - Specificky vyzkum na vysokych skolach

Publication year

2011

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Annals of Neurology

ISSN

0364-5134

e-ISSN

—

Volume of the periodical

69

Issue of the periodical within the volume

1

Country of publishing house

US - UNITED STATES

Number of pages

8

Pages from-to

75-82

UT code for WoS article

—

EID of the result in the Scopus database

—